Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities

about

Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities

Item

http://www.wikidata.org/entity/Q57069976

description

article

@en

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@en

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@nl

type

Item

label

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@en

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@nl

prefLabel

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@en

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@nl

P1476

Mechanisms, monitoring, and ma ...... ated cardiovascular toxicities

@en

P2093

Jeff Kamta

http://www.w3.org/2001/XMLSchema#string

Sihem Ait-Oudhia

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Sorafenib in advanced hepatocellular carcinoma

Twenty years of anti-HER2 therapy-associated cardiotoxicity

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

A quantitative analysis of kinase inhibitor selectivity

Sorafenib in advanced clear-cell renal-cell carcinoma

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

P304

6227-6237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S170138

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maher Chaar

P577

2018-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30288058

http://www.w3.org/2001/XMLSchema#string

P932

6163027

http://www.w3.org/2001/XMLSchema#string